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One Bad Allele
The DNA-repair enzyme 
CHEK2 is upregulated in 
response to UV exposure. 
Heterozygosity for the 
nonfunctioning frameshift 
CHEK2*1100delC germline 
alteration has been shown to 
increase the risk of developing 
breast cancer. In a case–
control study involving Danish 
and German patients and 
subsequent meta-analysis, 
Weischer and colleagues 
discovered that heterozygous 
carriers of this mutation have 
a twofold increased risk of 
malignant melanoma compared 
with noncarriers. This finding 
was understandable because 
these carriers have an impaired 
ability to recognize and repair 
UV-induced DNA breaks.  
See page 299  
Common  
Risk Factors
Recent studies have focused 
on the prevalence of 
comorbidities, including 
insulin resistance, metabolic 
syndrome, and type 2 diabetes 
(T2D), associated with psoriasis. 
In a prospective study of 
184,395 participants, Li and 
colleagues found a significantly 
higher risk of T2D associated 
with psoriasis among younger 
women. These findings not only 
support psoriasis as a systemic 
inflammatory disease but also 
suggest that psoriasis is a risk 
predictor for T2D. Furthermore, 
immune-mediated 
inflammatory processes, 
metabolic biomarkers, and 
environmental factors may be 
the links between psoriasis 
and diabetes; thus, these 
possibilities warrant further 
research. See page 291  
The Case against UVA
UVB “signature mutations,” which result from 
unrepaired cyclobutane pyrimidine dimers 
(CPDs) and pyrimidine (6-4) pyrimidone pho-
toproducts (6-4PPs), are commonly found in 
skin cancers. Although UVA1 (340–400 nm) is 
increasingly used for phototherapy, these wave-
lengths induce CPDs in cultured cells. Tewari 
and colleagues found that erythemally equivalent 
doses of UVA1 and UVB induce CPDs, but only 
UVB induces 6-4PPs in human skin. Although UVB induced more CPDs than UVA1 at 
a given exposure, UVA1-induced CPDs were more prominent in the lower epidermis, 
suggesting that the basal layer is particularly vulnerable to UVA1-induced damage. These 
data highlight the need for broader-waveband photoprotection. See page 394  
Beware the Sand Flies
Investigating a possible etiologic link between 
pemphigus and zoonotic cutaneous leishmaniasis 
(ZCL), which is caused by sand fly (Phlebotomus 
papatasi)–transmitted Leishmania major, Zaraa and 
colleagues discovered that the prevalence of desmo-
glein 1 serum antibodies, which are implicated in 
the pathogenesis of pemphigus, was higher in ZCL 
patients than in controls. Furthermore, the preva-
lence and serum levels of antibodies against P. papatasi salivary gland extracts were also 
higher in the pemphigus group. These results indicate that an environmental component 
may initiate the autoimmune response in pemphigus and suggest that exposure to P. papatasi 
may be an etiologic link to pemphigus in Tunisia, where ZCL is endemic. See page 479
Catching Up with Briakinumab
A phase II study of briakinumab 
previously demonstrated that 
this fully human anti- IL-12/23 
monoclonal antibody was 
efficacious for the treat-
ment of moderate to severe 
psoriasis, which is mediated 
by both T helper 1– and IL-17-
releasing T cells. Gordon 
and colleagues conducted a 
large, randomized, placebo-
controlled trial of briakinumab 
maintenance. Although main-
tenance with briakinumab 
every 4 weeks resulted in higher response rates than less frequent drug or placebo 
treatment, a greater number of adverse reactions, including skin cancers, infections, 
and cardiovascular events, occurred in this group. Thus, targeting IL-12/23 is a useful 
therapeutic approach for severe psoriasis; however, the risk of adverse events should 
be considered before therapy. See page 304  
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